A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer

Trial Profile

A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms PASSPORT
  • Sponsors Genentech
  • Most Recent Events

    • 01 Sep 2009 Actual patient number (115) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Nov 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top